These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38520607)

  • 1. Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching.
    Cohen HP; Bodenmueller W
    BioDrugs; 2024 May; 38(3):331-339. PubMed ID: 38520607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
    BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.
    Benucci M; Gobbi FL; Bandinelli F; Damiani A; Infantino M; Grossi V; Manfredi M; Parisi S; Fusaro E; Batticciotto A; Sarzi-Puttini P; Atzeni F; Meacci F
    Immunol Res; 2017 Feb; 65(1):419-422. PubMed ID: 27449503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
    Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
    Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
    Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
    Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
    Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
    Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
    Blair HA; Deeks ED
    BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
    Feagan BG; Lam G; Ma C; Lichtenstein GR
    Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
    McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of switching to adalimumab biosimilar (MSB11022) in patients with rheumatoid arthritis: RESTART Spanish Registry.
    García-Miguel J; Yankova Komsalova L; Mata Arnaiz C; Alegre-Sancho JJ; González Polo J; Torrente-Segarra V; Tornero Molina J; Navarro Angeles VA; Caramés C; Cristóbal I
    Curr Med Res Opin; 2024 Aug; 40(8):1431-1438. PubMed ID: 38932718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GP2015: An Etanercept Biosimilar.
    Deeks ED
    BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SB2: An Infliximab Biosimilar.
    Lamb YN; Scott LJ; Deeks ED
    BioDrugs; 2017 Oct; 31(5):461-464. PubMed ID: 28803431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab biosimilar GP1111: a review of 5 years' post-approval experience.
    Huizinga TWJ; Dipasquale V; Zabransky M; Heyn J; Romano C
    Expert Opin Biol Ther; 2024 Jul; 24(7):615-625. PubMed ID: 38976286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.
    Avouac J; Moltó A; Abitbol V; Etcheto A; Salcion A; Gutermann L; Klotz C; Elhai M; Cohen P; Soret PA; Morin F; Conort O; Chast F; Goulvestre C; Jeunne CL; Chaussade S; Kahan A; Roux C; Allanore Y; Dougados M
    Semin Arthritis Rheum; 2018 Apr; 47(5):741-748. PubMed ID: 29102156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
    Gaylis N; Both C; Lemke L; von Richter O; Yamauchi P
    Adv Ther; 2024 May; 41(5):1795-1814. PubMed ID: 38514505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.